STOCK TITAN

HeartSciences Warrant (HSCSW) 10-K Filings

HSCSW NASDAQ

Here are the 10-K annual reports from HeartSciences Inc. Warrant (HSCSW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow HSCSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCSW filings page.

Rhea-AI Summary

HeartSciences Inc. is a Texas-based healthcare IT company focused on AI-enabled electrocardiography. Its core product, MyoVista Insights, is a cloud-native, device-agnostic ECG management and AI-ECG orchestration platform classified as an MDDS and exempt from FDA 510(k) clearance. Early adopter deployments began in 2025, with a major upgrade and Epic Toolbox designation in March 2026.

The company is also developing the MyoVista wavECG, a 12-lead ECG device designed to host embedded AI algorithms. A 510(k) submission was filed in December 2025 and remains under FDA review; clearance and algorithm integration are critical to the device’s future success.

Financially, HeartSciences remains early-stage, with Fiscal 2026 net loss of $9.1 million, accumulated deficit of $85.3 million, and stockholders’ equity of about $0.2 million as of April 30, 2026. Its auditor raised substantial doubt about its ability to continue as a going concern. The company expects further capital needs, has all assets pledged as collateral, and anticipates receiving a new Nasdaq notice because equity is below the $2.5 million listing threshold, creating delisting risk despite a prior 1-for-100 reverse split in 2024. HeartSciences qualifies as an emerging growth and smaller reporting company, allowing reduced disclosures.